Investor Relations
Vivos Therapeutics, Inc. NASDAQ: VVOS
Vivos Therapeutics, Inc.
First Quarter 2022 Earnings Call
An Important Breakthrough in the Treatment for Mild-to-Moderate Obstructive Sleep Apnea
Vivos offers a multidisciplinary treatment protocol that uses nonsurgical, noninvasive, and cost-effective oral appliance technology prescribed by trained dentists and medical professionals to treat dentofacial abnormalities and/or mild-to-moderate OSA. This revolutionary treatment is called The Vivos Method.
Latest Stock Information
Listen to Kirk Huntsman and Brad Amman at the
34th Annual Roth Conference
Investor Presentation
Download the Vivos Investor Presentation
Fast Company Selects Vivos Therapeutics for 2022
“World’s Most Innovative Companies” List
Corporate Leadership
Our leadership team is devoted to a singular mission: to rid the world of sleep apnea.
News
Vivos Therapeutics’ SLEEP 2022 Annual Meeting Presentation Highlights Retrospective Study Demonstrating Significant Improvement in Sleep Apnea
Study Recently Presented at the SLEEP 2022 Annual Meeting LITTLETON Colorado, June, 14, 2022 GLOBE NEWSWIRE) -- Vivos Therapeutics,...
Vivos Therapeutics Schedules First Quarter 2022 Financial Results Conference Call
Call Scheduled for Monday, May 16, 2022 at 5:00 pm ET HIGHLANDS RANCH Colorado, April 28, 2022 GLOBE NEWSWIRE) -- Vivos Therapeutics,...
Vivos Therapeutics Opens Third U.S. Multidisciplinary Center to Treat Patients Suffering from Sleep Apnea with The Vivos Method
New Pneusomnia Center in Toluca Lake, Calif., Will Combine Medical and Dental Expertise to Provide Comprehensive Care for Complex Airway Issues...